SCHEMBL411806

SCHEMBL411806

CCOC(=O)C(C#N)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 5/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 4/20 0.39
GAA P10253 3/20 0.39
MEN1 O00255 3/20 0.39
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
HSD17B10 Q99714 1/20 0.37
MAPK1 P28482 1/20 0.36
ALOX15 P16050 1/20 0.36
MGAM O43451 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
SOAT1 P35610 1/20 0.36
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10535054 0.89 SMN1; SMN2 (0.45) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL7706526 0.88 SMN1; SMN2 (0.40) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL28515317 0.86 SMN1; SMN2 (0.40) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL6925027 0.85 SMN1; SMN2 (0.41) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL13858310 0.85 SMN1; SMN2 (0.41) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL6925032 0.85 SMN1; SMN2 (0.41) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL6925024 0.85 SMN1; SMN2 (0.41) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL5524988 0.84 SMN1; SMN2 (0.39) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL23130401 0.83 SMN1; SMN2 (0.40) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A
SCHEMBL24229968 0.82 ALDH1A1 (0.46) SMN1; SMN2L3MBTL1ALDH1A1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2399902-B1 PROCESS FOR PREPARING 2,3-DI-NON-STRAIGHT-ALKYL-2-CYANO SUCCINIC ACID DIESTERS CHINA PETROLEUM & CHEMICAL (CN) 2014-11-26 EP claimed
US-8669392-B2 Process for preparing 2,3-di-non-straight-alkyl-2-cyanosuccinic acid diesters CHINA PETROLEUM & CHEMICAL CORPORATION (CN) 2014-03-11 US claimed
US-20120046490-A1 PROCESS FOR PREPARING 2,3-DI-NON-STRAIGHT-ALKYL-2-CYANOSUCCINIC ACID DIESTERS CHINA PETROLEUM & CHEMICAL CORPORATION (CN) 2012-02-23 US claimed
EP-2399902-A1 PROCESS FOR PREPARING 2,3-DI-NON-STRAIGHT-ALKYL-2-CYANO SUCCINIC ACID DIESTERS China Petroleum & Chemical Corporation (CN) 2011-12-28 EP claimed
EP-0938509-B1 COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS BASELL POLIOLEFINE SPA (IT) 2002-11-20 EP claimed
US-6143684-A FOR STEREOSPECIFIC POLYMERIZATION OF OLEFINS SUCH AS PROPYLENE MONTELL TECHNOLOGY COMPANY B.V. (NL) 2000-11-07 US claimed
EP-0938509-A1 COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS Montell Technology Company bv (NL) 1999-09-01 EP claimed
WO-1999011677-A1 COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS MONTELL TECHNOLOGY COMPANY B.V. (NL) 1999-03-11 WO claimed
EP-4688778-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Biogen MA Inc. (US) 2026-02-11 EP disclosed
EP-4524129-A1 METHOD FOR PREPARING 2-SUBSTITUTED ARYL ACETONITRILE COMPOUND AND USE THEREOF Maxunitech Inc. (CN) 2025-03-19 EP disclosed
US-20250059132-A1 METHOD FOR PREPARING 2-SUBSTITUTED ARYLACETONITRILE COMPOUND AND APPLICATION THEREOF MAXUNITECH INC (CN) 2025-02-20 US disclosed
WO-2024211696-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES BIOGEN MA INC. (US) 2024-10-10 WO disclosed
CN-118330121-A Method for determining characteristic aroma components of rambutan seed oil by combining GC-MS and GC-IMS 海南大学 2024-07-12 CN disclosed
CN-117069614-A Preparation method and application of 2-substituted aryl acetonitrile compound 合力科技股份有限公司 2023-11-17 CN disclosed
US-6153591-A PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS CYTOVIA, INC. (US) 2000-11-28 US disclosed
US-6143684-A FOR STEREOSPECIFIC POLYMERIZATION OF OLEFINS SUCH AS PROPYLENE MONTELL TECHNOLOGY COMPANY B.V. (NL) 2000-11-07 US disclosed
WO-1999047154-A1 DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA, INC. (US) 1999-09-23 WO disclosed
EP-0938509-A1 COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS Montell Technology Company bv (NL) 1999-09-01 EP disclosed
WO-1999011677-A1 COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS MONTELL TECHNOLOGY COMPANY B.V. (NL) 1999-03-11 WO disclosed
US-4141915-A REACTING AN UNSATURATED NITRILE, AN ALCOHOL, AND CARBON MONOXIDE DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1979-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046490-A1 PROCESS FOR PREPARING 2,3-DI-NON-STRAIGHT-ALKYL-2-CYANOSUCCINIC ACID DIESTERS ACMSD, ADSL, CNDP2 SMN1; SMN2 490/4885L3MBTL1 4547/4885ALDH1A1 1240/4885
US-20250059132-A1 METHOD FOR PREPARING 2-SUBSTITUTED ARYLACETONITRILE COMPOUND AND APPLICATION THEREOF CYP1B1, CYP1A2, CYP2C9 SMN1; SMN2 2364/4885L3MBTL1 4731/4885ALDH1A1 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.